Pacific Biosciences Reports Second Quarter 2014 Financial Results
July 24 2014 - 4:00PM
Pacific Biosciences of California, Inc. (Nasdaq:PACB) today
reported an 89% increase in revenue to $11.4 million for the second
quarter, compared to $6.0 million for the second quarter of 2013.
Second quarter 2014 revenue reflects the delivery of eight
PacBio® RS II systems, compared to three systems during the second
quarter of 2013. Total revenue for the second quarter of 2014 also
included $1.7 million of contractual revenue. The Company booked
five PacBio RS II instrument orders during the period and ended the
quarter with 10 instruments in backlog.
Gross profit for the quarter increased 195% to $3.1 million,
resulting in a gross margin of 27.4%, compared to gross profit of
$1.1 million and a gross margin of 17.5% for the second quarter of
2013.
Operating expenses totaled $21.4 million for the quarter,
compared to $21.1 million for the second quarter of 2013. Operating
expenses for the second quarters of 2014 and 2013 included non-cash
stock-based compensation of $2.1 million and $2.3 million,
respectively.
The net loss for the quarter was $19.1 million, compared to
$20.5 million for the second quarter of 2013.
Cash and investments at June 30, 2014 totaled $105.0 million,
compared to $112.5 million at December 31, 2013.
Quarterly Conference Call Information
Management will host a quarterly conference call to discuss its
second quarter 2014 results today at 4:30 p.m. Eastern Time.
Investors may listen to the call by dialing 1.888.366.7247, or if
outside the U.S., by dialing +1.707.287.9330. The call will be
webcast live and will be available for replay at Pacific
Biosciences' website at
http://investor.pacificbiosciences.com/.
About Pacific Biosciences
Pacific Biosciences of California, Inc. (Nasdaq:PACB) offers the
PacBio® RS II Sequencing System to help scientists solve
genetically complex problems. Based on its novel Single Molecule,
Real-Time (SMRT®) Sequencing technology, the company's products
enable: targeted sequencing to more comprehensively characterize
genetic variations; de novo genome assembly to more fully identify,
annotate and decipher genomic structures; and DNA base modification
identification to help characterize epigenetic regulation and DNA
damage. By providing access to information that was previously
inaccessible, Pacific Biosciences enables scientists to increase
their understanding of biological systems.
Forward-Looking Statements
This press release contains forward-looking statements that
involve risks and uncertainties. Forward-looking statements are
based on management's beliefs and assumptions and on information
currently available to them. The Company's actual results could
differ materially from those anticipated in these forward-looking
statements for many reasons, including the risks faced by us and
described in the Company's most recently filed Quarterly Report on
Form 10-Q, Annual Report on Form 10-K, or the Company's other
filings with the SEC, as the case may be. You should not place
undue reliance on forward-looking statements, which apply only as
of the date of this press release. The Company assumes no
obligation to update these forward-looking statements.
|
Pacific Biosciences of
California, Inc. |
Unaudited Condensed
Consolidated Statement of Operations |
(amounts in thousands,
except per share amounts) |
|
|
|
|
|
|
|
|
|
|
|
Three-month
Periods Ended June 30, |
Six-month Periods
Ended June 30, |
|
2014 |
2013 |
2014 |
2013 |
Revenue: |
|
|
|
|
Product revenue |
$ 7,749 |
$ 4,601 |
$ 15,614 |
$ 8,434 |
Service and other revenue |
1,980 |
1,447 |
4,061 |
3,192 |
Contractual revenue |
1,696 |
— |
3,392 |
— |
Total revenue |
11,425 |
6,048 |
23,067 |
11,626 |
Cost of Revenue: |
|
|
|
|
Cost of product revenue |
6,271 |
3,322 |
13,440 |
6,522 |
Cost of service and other
revenue |
2,028 |
1,667 |
3,825 |
3,115 |
Total cost of revenue |
8,299 |
4,989 |
17,265 |
9,637 |
Gross profit |
3,126 |
1,059 |
5,802 |
1,989 |
Operating Expense: |
|
|
|
|
Research and development |
12,435 |
11,682 |
24,206 |
23,665 |
Sales, general and
administrative |
8,993 |
9,374 |
18,143 |
18,928 |
Total operating expense |
21,428 |
21,056 |
42,349 |
42,593 |
Operating loss |
(18,302) |
(19,997) |
(36,547) |
(40,604) |
Interest expense |
(701) |
(673) |
(1,387) |
(1,098) |
Other income (expense), net |
(133) |
199 |
(88) |
127 |
Net loss |
$ (19,136) |
$ (20,471) |
$ (38,022) |
$ (41,575) |
Basic and diluted net loss per
share |
$ (0.27) |
$ (0.33) |
$ (0.55) |
$ (0.70) |
Shares used in computing basic and diluted
net loss per share |
70,515 |
61,922 |
69,195 |
59,660 |
|
Pacific Biosciences of
California, Inc. |
Unaudited Condensed
Consolidated Balance Sheets |
(amounts in
thousands) |
|
|
|
|
|
|
|
|
|
June 30, |
March 31, |
December 31, |
|
2014 |
2014 |
2013 |
Assets |
|
|
|
Cash and investments |
$ 105,034 |
$ 118,736 |
$ 112,528 |
Accounts receivable |
4,255 |
3,383 |
2,746 |
Inventory |
9,440 |
8,301 |
10,050 |
Prepaid and other current
assets |
1,169 |
1,642 |
1,135 |
Property and equipment |
7,861 |
8,492 |
9,236 |
Other long-term Assets |
482 |
486 |
490 |
Total Assets |
$ 128,241 |
$ 141,040 |
$ 136,185 |
|
|
|
|
Liabilities and Stockholders'
Equity |
|
|
|
Accounts payable |
$ 5,379 |
$ 3,926 |
$ 1,717 |
Accrued expenses |
9,225 |
6,625 |
8,766 |
Deferred service revenue |
6,146 |
4,822 |
4,564 |
Deferred contractual revenue |
29,912 |
31,608 |
33,304 |
Other liabilities |
4,151 |
4,460 |
4,758 |
Financing derivative |
699 |
549 |
549 |
Notes payable |
13,714 |
13,525 |
13,347 |
Stockholders' equity |
59,015 |
75,525 |
69,180 |
Total Liabilities and Stockholders'
Equity |
$ 128,241 |
$ 141,040 |
$ 136,185 |
CONTACT: Trevin Rard
650.521.8450
ir@pacificbiosciences.com
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Apr 2023 to Apr 2024